000167183 001__ 167183
000167183 005__ 20240229133532.0
000167183 0247_ $$2doi$$a10.1016/j.ejrad.2021.109538
000167183 0247_ $$2pmid$$apmid:33482592
000167183 0247_ $$2altmetric$$aaltmetric:98834324
000167183 037__ $$aDKFZ-2021-00174
000167183 041__ $$aeng
000167183 082__ $$a610
000167183 1001_ $$0P:(DE-He78)aec14a1077ed145f9ebe9de1d50905b0$$aWang, Xianfeng$$b0$$eFirst author$$udkfz
000167183 245__ $$aComparison of single-scanner single-protocol quantitative ADC measurements to ADC ratios to detect clinically significant prostate cancer.
000167183 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2021
000167183 3367_ $$2DRIVER$$aarticle
000167183 3367_ $$2DataCite$$aOutput Types/Journal article
000167183 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692790952_30742
000167183 3367_ $$2BibTeX$$aARTICLE
000167183 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167183 3367_ $$00$$2EndNote$$aJournal Article
000167183 500__ $$a#EA:E010#LA:E010#
000167183 520__ $$aMean ADC has high predictive value for the presence of clinically significant prostate cancer (sPC). Measurement variability is introduced by different scanners, protocols, intra-and inter-patient variation. Internal calibration by ADC ratios can address such fluctuations however can potentially lower the biological value of quantitative ADC determination by being sensitive to deviations in reference tissue signal.To better understand the predictive value of quantitative ADC measurements in comparison to internal reference ratios when measured in a single scanner, single protocol setup.284 consecutive patients who underwent 3 T MRI on a single scanner followed by MRI-transrectal ultrasound fusion biopsy were included. A board-certified radiologist retrospectively reviewed all MRIs blinded to clinical information and placed regions of interest (ROI) on all focal lesions and the following reference regions: normal-appearing peripheral zone (PZNL) and transition zone (TZNL), the urinary bladder (BLA), and right and left internal obturator muscle (RIOM, LIOM). ROI-based mean ADC and ADC ratios to the reference regions were compared regarding their ability to predict the aggressiveness of prostate cancer. Spearman's rank correlation coefficient was used to estimate the correlation between ADC parameters, Gleason score (GS) and ADC ratios. The primary endpoint was presence of sPC, defined as a GS ≥ 3 + 4. Univariable and multivariable logistic regression models were constructed to predict sPC. Receiver operating characteristics curves (ROC) were used for visualization; DeLong test was used to evaluate the differences of the area under the curve (AUC). Bias-corrected AUC values and corresponding 95 %-CI were calculated using bootstrapping with 100 bootstrap samples.After exclusion of patients who received prior treatment, 259 patients were included in the final cohort of which 220 harbored 351 MR lesions. Mean ADC and ADC ratios demonstrated a negative correlation with the GS. Mean ADC had the strongest correlation with ρ of -0.34, followed by ADCratioPZNL (ρ=-0.32). All ADC parameters except ADCratioLIOM (p = 0.07) were associated with sPC p<0.05). Mean ADC and ADCratioPZNL had the highest ROC AUC of all parameters (0.68). Multivariable models with mean ADC improve predictive performance.A highly standardized single-scanner mean ADC measurement could not be improved upon using any of the single ADC ratio parameters or combinations of these parameters in predicting the aggressiveness of prostate cancer.
000167183 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000167183 588__ $$aDataset connected to CrossRef, PubMed,
000167183 650_7 $$2Other$$aApparent diffusion coefficient
000167183 650_7 $$2Other$$aGleason score
000167183 650_7 $$2Other$$aMultiparametric MRI
000167183 650_7 $$2Other$$aProstate cancer
000167183 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000167183 7001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan Philipp$$b2$$udkfz
000167183 7001_ $$aGörtz, Magdalena$$b3
000167183 7001_ $$aSchütz, Viktoria$$b4
000167183 7001_ $$0P:(DE-He78)59dfdd0ee0a7f0db81535f0781a3a6d6$$aKuder, Tristan Anselm$$b5$$udkfz
000167183 7001_ $$0P:(DE-He78)77bc493068847c689d894d2eda891c0c$$aGnirs, Regula$$b6$$udkfz
000167183 7001_ $$aSchwab, Constantin$$b7
000167183 7001_ $$aStenzinger, Albrecht$$b8
000167183 7001_ $$aHohenfellner, Markus$$b9
000167183 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b10$$udkfz
000167183 7001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b11$$eLast author$$udkfz
000167183 773__ $$0PERI:(DE-600)2005350-2$$a10.1016/j.ejrad.2021.109538$$gVol. 136, p. 109538 -$$p109538$$tEuropean journal of radiology$$v136$$x0720-048X$$y2021
000167183 909CO $$ooai:inrepo02.dkfz.de:167183$$pVDB
000167183 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)aec14a1077ed145f9ebe9de1d50905b0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000167183 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000167183 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000167183 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)59dfdd0ee0a7f0db81535f0781a3a6d6$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000167183 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77bc493068847c689d894d2eda891c0c$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000167183 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000167183 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000167183 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000167183 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000167183 9141_ $$y2021
000167183 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-09-29$$wger
000167183 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-29
000167183 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-29
000167183 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-29
000167183 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-29
000167183 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-29
000167183 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-29
000167183 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-29
000167183 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J RADIOL : 2018$$d2020-09-29
000167183 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-29
000167183 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-29
000167183 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-09-29
000167183 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000167183 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000167183 9201_ $$0I:(DE-He78)E020-20160331$$kE020$$lE020 Med. Physik in der Radiologie$$x2
000167183 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000167183 980__ $$ajournal
000167183 980__ $$aVDB
000167183 980__ $$aI:(DE-He78)E010-20160331
000167183 980__ $$aI:(DE-He78)C060-20160331
000167183 980__ $$aI:(DE-He78)E020-20160331
000167183 980__ $$aI:(DE-He78)HD01-20160331
000167183 980__ $$aUNRESTRICTED